Petra Capital has released a research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell applies for TGA market approval for SmrtGraft™
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Remplir™ nerve repair study published in peer-reviewed clinical journal
Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical journal.
Orthocell receives $3.05m R&D tax incentive refund
Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Quarterly Report – Period To 31 March 2024
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Proactive Interview with Paul Anderson
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplir™.
Orthocell Successfully Completes Surgeries for Remplir™ US Market Authorisation
Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair study.
Proactive | Interview with CEO Paul Anderson
Orthocell CEO Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
The West Australian | Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
Orthocell’s Company-led strategic placement has been reported in The West Australian newspaper today, in an article by Senior Business Report Sean Smith titled “Chris Ellison, Rod Jones and the McCuskers jump into Orthocell”.
Orthocell Completes $3.5M Strategic Placement
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.